Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Sevilla – page 8

1 657 clinical trials in Sevilla, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Sevilla at a glance
1 657
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 657 trials in Sevilla

Open in trial search

Non-small cell lung cancer metastatic

Recruiting

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986340
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Chronic graft versus host disease

Recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Type 2 diabetes mellitus

Recruiting

Efficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Neoplasm

Recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Renal transplant

Recruiting

Safety of Two Doses of Siplizumab Compared with Rabbit Anti‑Human Thymocyte Immunoglobulin in Kidney Transplant Recipients Receiving Standard Immunosuppression

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Siplizumab

Adenocarcinoma pancreas

Recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Malignant melanoma stage III

Recruiting

A Randomized Double‑Blind Study of Pharmacokinetic Similarity of AVT32‑DRL_PB and Pembrolizumab in Patients with Resected Stage IIB‑C‑III Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Alvotech Swiss AG

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Plasma cell myeloma

Recruiting

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Lipoprotein (a) increased

Recruiting

Phase 2 study of MK-7262 and enlicitide decanoate in adults with high lipoprotein(a)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Sharp & Dohme LLC

Pneumococcal immunisation

Recruiting

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:PF-07831695
  • Sponsor:Pfizer Inc.

Immune thrombocytopenia

Recruiting

Phase 3 Study of Romiplostim Combined with Prednisolone versus Prednisolone Alone in Adults with Previously Untreated Primary Immune Thrombocytopenia (ITP)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Amgen Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Sevilla

What the registry says about research in the country

01 Metabolic and Endocrine Disorders

Innovative research focusing on Type 1 Diabetes management and weight-related conditions, evaluating new therapeutic approaches for glycemic control and metabolic health.

  • Diabetes Management
  • Obesity Treatment
  • Metabolic Disorders

Studies aim to improve treatment outcomes for patients with complex metabolic conditions.

02 Neurological Conditions

Advanced clinical trials examining treatments for Multiple Sclerosis and neurodegenerative disorders, including pioneering research in Frontotemporal Dementia and Parkinson's disease.

  • Multiple Sclerosis Therapies
  • Neurodegenerative Diseases
  • Brain Health Innovation

Research focuses on developing targeted treatments for various neurological conditions.

03 Infectious Diseases

Comprehensive vaccine development programs targeting Influenza, Cytomegalovirus, and meningococcal infections, with emphasis on preventive medicine.

  • Vaccine Development
  • Viral Infections
  • Immunization Studies

Studies aim to enhance vaccine efficacy and immune response across different age groups.

04 Oncology Research

Groundbreaking studies in cancer treatment, including research on bladder cancer and mantle cell lymphoma, exploring combination therapies and targeted treatments.

  • Cancer Immunotherapy
  • Targeted Therapies
  • Combination Treatments

Focus on developing innovative approaches to improve cancer treatment outcomes.

05 Autoimmune Conditions

Clinical investigations into Psoriatic Arthritis and inflammatory conditions, evaluating novel therapeutic approaches and treatment combinations.

  • Arthritis Treatment
  • Inflammatory Diseases
  • Immune System Disorders

Research aims to develop more effective treatments for chronic autoimmune conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.